Back to results
US 9,808,477 B2Granted
Use of nobiletin in cancer treatment
AssigneeMacau University of Science and Technology
InventorsWen-zhe Ma, Sen-ling Feng, Xiao-jun Yao, Zhong-wen Yuan, Liang Liu, Ying Xie
Life of this patent
Estimating the term…
Abstract
The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.
Claims8
A method of treating multidrug resistance cancer, comprising:
- administering a pharmaceutically effective amount of a citrus methoxyflavone and a chemotherapeutic drug to a subject in need thereof,
- wherein the citrus methoxyflavone is nobiletin, the chemotherapeutic drug is paclitaxel, and the multidrug resistance cancer is paclitaxel-resistant ovarian cancer;
- wherein the paclitaxel and the nobiletin are administered to the subject in a molar ratio of 0.94:0.5 to 0.94:9 to treat the paclitaxel-resistant ovarian cancer.
A method of enhancing an efficacy of a chemotherapeutic drug to treat multidrug resistance cancer, comprising:
- administering the chemotherapeutic drug to a subject;
- and
- applying a citrus methoxyflavone to the subject,
- wherein the citrus methoxyflavone is nobiletin, the chemotherapeutic drug is paclitaxel, and the multidrug resistance cancer is paclitaxel-resistant ovarian cancer;
- wherein the paclitaxel and the nobiletin are administered to the subject in a molar ratio of 0.94:0.5 to 0.94:9 to treat the paclitaxel-resistant ovarian cancer.
2 more elements
Dependencies are inferred from the claim text.